Publications

At Ichnos Sciences, we’re working to make real progress in science and medicine. Explore our recent publications to discover how we’re shifting medicine forward. 

Date
Subject: All
All BEAT® Antibody Engineering Platform Cell Line Development ISB 1342 ISB 1442 ISB 2001 ISB 830
Title Lead Author Journal
05/22/2023 ISB 1342 Pre-clinical Characterization of ISB 1342, a CD38xCD3 T-cell Engager for Relapsed/Refractory Multiple Myeloma Perro M. et al. Blood
04/17/2023 ISB 2001 Overcoming Mechanisms of Escape from Treatments for Multiple Myeloma by ISB 2001, a first-in-Class Trispecific BCMA and CD38 targeted T Cell Engager (PDF) Perro M. et al. American Association for Cancer Research Annual Meeting
12/12/2022 ISB 1442 Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (PDF) Jiang T. et al. American Society of Hematology Annual Meeting
12/12/2022 ISB 1442 Presentation: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (PDF) Jiang T. et al. Presentation at the American Society of Hematology Annual Meeting
12/11/2022 ISB 1342 Poster: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) (PDF) Mohan S. et al. American Society of Hematology Annual Meeting
12/11/2022 ISB 1342 Presentation: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) (PDF) Mohan S. et al. Presentation at the American Society of Hematology Annual Meeting
12/11/2022 ISB 1442 Poster: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL (PDF) Sammicheli S. et al. American Society of Hematology Annual Meeting
12/11/2022 ISB 1442 Presentation: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL (PDF) Sammicheli S. et al. Presentation at the American Society of Hematology Annual Meeting
12/10/2022 ISB 2001 ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma by Targeting Two Antigens (PDF) Perro M. et al. Presentation at the American Society of Hematology Annual Meeting
06/28/2022 Optimization of a Cell Culture Clarification Platform Process With the Aim of Boosting the Recovery of Bispecific Antibodies (PDF) Mette R. et al. Presentation at ESACT2022 Conference

View Career Opportunities

Career Opportunities

The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.

Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.

X
Concerning Your Privacy
Access to an Ichnos Site may be monitored by Ichnos. If monitored, the requesting URLs, the machine originating the request and the time of the request are logged for access statistics and security purposes. Your use and access of an Ichnos Site constitutes your consent to such general monitoring. Please see the Ichnos Privacy Policy and Cookie Notice for details on how information from the Site may be gathered and used.